Pozen Inc. (POZN) Jumps 9.58% on January 22

Equities Staff |

Pozen Inc. (POZN) was among the biggest gainers on the Russell 2000 for Friday January 22 as the stock popped 9.58% to $6.47, representing a gain of $0.565 per share. Some 288,350 shares traded hands on 2,052 trades, compared with an average daily volume of 504,876 shares out of a total float of 32.78 million. The stock opened at $6.06 and traded with an intraday range of $6.54 to $6.01.

After today's gains, Pozen Inc. reached a market cap of $211.91 million. Pozen Inc. has had a trading range between $12.69 and $5.49 over the last year, and it had a 50-day SMA of $6.81 and a 200-day SMA of $8.11.

POZEN Inc is a pharmaceutical company engaged in developing products that address unmet medical needs in the marketplace.

Pozen Inc. is based out of Chapel Hill, NC and has some 12 employees. Its CEO is Adrian Adams.

For a complete fundamental analysis analysis of Pozen Inc., check out Equities.com’s Stock Valuation Analysis report for POZN. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Emerging Growth

Beleave Inc.

Beleave Inc is a biotech company. The Company is engaged in the production of medical marijuana under the Marihuana for Medical Purposes Regulations outlined by Health Canada.

Private Markets


Our mission is to be the best place for people who care about music to create and discover thoughtfully curated playlists. In essence, 8tracks is a platform for online mixtapes.


Trustify provides trust and safety in both the digital and physical worlds through our vast network of on-demand Private Investigators.By removing the large retainers and high hourly rates that traditional…